BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 15791505)

  • 1. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
    Reuter S; Kern WV; Sigge A; Döhner H; Marre R; Kern P; von Baum H
    Clin Infect Dis; 2005 Apr; 40(8):1087-93. PubMed ID: 15791505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxifloxacin prophylaxis in neutropenic patients.
    von Baum H; Sigge A; Bommer M; Kern WV; Marre R; Döhner H; Kern P; Reuter S
    J Antimicrob Chemother; 2006 Oct; 58(4):891-4. PubMed ID: 16880172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical study on fluoroquinolone prophylaxis in neutropenia patients with acute leukemia].
    Qin TJ; Mi YC; Feng SZ; Li DP; Wei JL; Yang DL; Han MZ; Wang JX; Bian SG
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(20):1389-93. PubMed ID: 17785058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fluoroquinolone prophylaxis utility during chemotherapy-induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City].
    Ugarte-Torres A; Villasis-Keever A; Hernández-Bribiesca ME; Crespo-Solis E; Ruiz-Palacios GM; Sifuentes-Osornio J; Ponce-De-León-Garduño A
    Rev Invest Clin; 2006; 58(6):547-54. PubMed ID: 17432285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.
    Bucaneve G; Micozzi A; Menichetti F; Martino P; Dionisi MS; Martinelli G; Allione B; D'Antonio D; Buelli M; Nosari AM; Cilloni D; Zuffa E; Cantaffa R; Specchia G; Amadori S; Fabbiano F; Deliliers GL; Lauria F; Foà R; Del Favero A;
    N Engl J Med; 2005 Sep; 353(10):977-87. PubMed ID: 16148283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit.
    Craig M; Cumpston AD; Hobbs GR; Devetten MP; Sarwari AR; Ericson SG
    Bone Marrow Transplant; 2007 Apr; 39(8):477-82. PubMed ID: 17322937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli.
    Gomez L; Garau J; Estrada C; Marquez M; Dalmau D; Xercavins M; Martí JM; Estany C
    Cancer; 2003 Jan; 97(2):419-24. PubMed ID: 12518366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution.
    Cattaneo C; Quaresmini G; Casari S; Capucci MA; Micheletti M; Borlenghi E; Signorini L; Re A; Carosi G; Rossi G
    J Antimicrob Chemother; 2008 Mar; 61(3):721-8. PubMed ID: 18218645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms.
    Rangaraj G; Granwehr BP; Jiang Y; Hachem R; Raad I
    Cancer; 2010 Feb; 116(4):967-73. PubMed ID: 20052728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.
    Leibovici L; Paul M; Cullen M; Bucaneve G; Gafter-Gvili A; Fraser A; Kern WV
    Cancer; 2006 Oct; 107(8):1743-51. PubMed ID: 16977651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.
    Kern WV; Klose K; Jellen-Ritter AS; Oethinger M; Bohnert J; Kern P; Reuter S; von Baum H; Marre R
    Eur J Clin Microbiol Infect Dis; 2005 Feb; 24(2):111-8. PubMed ID: 15714332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.
    Cullen M; Steven N; Billingham L; Gaunt C; Hastings M; Simmonds P; Stuart N; Rea D; Bower M; Fernando I; Huddart R; Gollins S; Stanley A;
    N Engl J Med; 2005 Sep; 353(10):988-98. PubMed ID: 16148284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies.
    Chong Y; Yakushiji H; Ito Y; Kamimura T
    Int J Infect Dis; 2011 Apr; 15(4):e277-81. PubMed ID: 21324723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia.
    Verlinden A; Jansens H; Goossens H; van de Velde AL; Schroyens WA; Berneman ZN; Gadisseur AP
    Eur J Haematol; 2014 Oct; 93(4):302-8. PubMed ID: 24750350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study.
    Slobbe L; Waal Lv; Jongman LR; Lugtenburg PJ; Rijnders BJ
    Eur J Cancer; 2009 Nov; 45(16):2810-7. PubMed ID: 19647995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
    Ann Intern Med; 1991 Jul; 115(1):7-12. PubMed ID: 2048868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates.
    Johnson L; Sabel A; Burman WJ; Everhart RM; Rome M; MacKenzie TD; Rozwadowski J; Mehler PS; Price CS
    Am J Med; 2008 Oct; 121(10):876-84. PubMed ID: 18823859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematological: Low all-cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: a single-center study.
    Kjellander C; Björkholm M; Cherif H; Kalin M; Giske CG
    Eur J Haematol; 2012 May; 88(5):422-30. PubMed ID: 22335785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gram-negative bacteremia in neutropenic patients with hematologic disorders. Experiences with prophylactic use of fluoroquinolones].
    Sinkó J; Cser V; Konkoly Thege M; Masszi T
    Orv Hetil; 2011 Jul; 152(27):1063-7. PubMed ID: 21676672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis.
    Busca A; Cavecchia I; Locatelli F; D'Ardia S; De Rosa FG; Marmont F; Ciccone G; Baldi I; Serra R; Gaido E; Falda M
    Transpl Infect Dis; 2012 Feb; 14(1):40-8. PubMed ID: 21599817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.